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Introduction
Fifty-seven years since warfarin was approved by the FDA, two new oral anticoagulants have entered the U.S. market. These drugs have given patients and providers alternatives to heparin and warfarin for prophylaxis against stroke in patients with atrial fibrillation and venous thromboembolism (VTE) after orthopedic procedures. As more patients have switched to these anticoagulants, issues have arisen such as management of bleeding and perioperative management. This review will focus on dabigatran and rivaroxaban as they are approved for clinical use and apixaban as it has completed phase III studies. The pharmacokinetic data for these agents is summarized in Table 1 . A review of the coagulation cascade and the sites of action of these agents are seen in Figure 1 . The new oral drugs are very effective anticoagulants because they inhibit proteins at the end of the coagulation cascade. Reversal of the anticoagulant effect is challenging because antidotes for these anticoagulants do not exist. This review will summarize available clinical trial evidence as well as a proposed approach to management of bleeding and the perioperative setting.
Dabigatran
Clinical Trials
Dabigatran is an oral direct thrombin inhibitor that is FDA approved for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation. The RE-LY trail randomized over 18,000 patients with non-valvular atrial fibrillation to blinded treatment with dabigatran 150 mg or 110 mg orally twice daily or open label warfarin (Table 2 ). Dabigatran 150 mg was superior to warfarin in prevention of stroke or systemic embolism with the primary end-point occurring in 1.11%/year of patients managed with dabigatran compared to 1.69%/year in patients treated with warfarin (p<0.001 superiority). The 110 mg dose was non-inferior to warfarin. The rate of ischemic stroke was significantly less only in patients treated with 150 mg of dabigatran.
Life threatening hemorrhage occurred less often with either dose of dabigatran.
Intracranial hemorrhage occurred significantly less in the dabigatran 110 mg and 150 mg groups compared to warfarin with a rate of 0.23%/year, 0.3%/year, and 0.74 %/year, respectively. 1 The FDA approved dabigatran (Pradaxa®; Boehringer Ingelheim, Ingelheim, Germany) 150 mg orally twice daily in October 2010 for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The 110 mg dose was not approved as subset analyses did not find a group in which the risk-benefit profile was superior to the 150 mg dose. 2 Based on pharmacokinetic data, 75 mg orally twice daily was approved for patients with creatinine clearance between 15-30 ml/min, but other authors suggest caution with use in this group. 3 Subsequent analysis has shown that poorly controlled patients on warfarin with INR measurements in therapeutic range <65% of the time benefited the most and may be the best candidates for dabigatran therapy. 4 A phase II placebo-controlled dose escalation study (50 to 150 mg twice daily) of dabigatran in patients after myocardial infarction showed equal rates of cardiovascular death, myocardial infarction and stroke, but a dose dependent increase in bleeding rates. 5 Additional studies of dabigatran for secondary prevention after acute coronary syndromes are not currently available.
Dabigatran has also been studied in prophylaxis of VTE after knee and hip replacement.
The RE-MODEL and RE-MOBILIZE trials compared 150mg and 220 mg of dabigatran to enoxaparin 40 mg subcutaneously daily or 30 mg subcutaneously twice daily, respectively. Both dabigatran doses were found have equal bleeding rates in comparison to enoxaparin. However, enoxaparin 30 mg twice daily was superior to dabigatran whereas dabigatran was non-inferior to enoxaparin 40 mg daily (Table 2) . 6 In a study of 2000 patients treated after total hip replacement VTE or death occurred in 2.2% of patients treated with dabigatran 220 mg compared to 4.2% of patients treated with enoxaparin 40 mg daily (risk difference -1.9%, p=0.03 superiority). Major bleeding was similar between the groups (1.4% dabigatran, 0.9% enoxaparin, p=0.4). 7 Overall this data suggests similar efficacy to enoxaparin 40 mg daily in VTE prophylaxis after orthopedic surgery with similar bleeding risk. Dabigatran has been approved in Europe and Canada for prevention of VTE after orthopedic surgery based on this data.
The RE-COVER trial examined the use of dabigatran to treat VTE in 2500 patients with proximal DVT or pulmonary embolism. All patients were treated with low-molecular weight heparin and then randomized to dabigatran 150 mg twice daily or warfarin for 6 months in a double-blind, double-dummy design. Recurrent VTE occurred in 2.4 % in the dabigatran arm and 2.1% in the warfarin group (p<0.001, non-inferiority). Major bleeding was equal but the location of bleeding was more often in a critical organ (9 intracranial hemorrhages with warfarin versus 1 intracranial hemorrhage with dabigatran). The incidence of any bleeding was also higher in the warfarin group (21.9% versus 16.1%, Hazard Ratio (HR) 0.71). 8 The RE-MEDY trial is an extension of the RE-COVER trial examining the use of dabigatran for secondary prevention of VTE. The study completed in October 2010 and we anticipate results in the next year.
Laboratory Testing
One of the major benefits of dabigatran over warfarin is that laboratory monitoring is not required during therapy. However, there are many instances in which knowing the degree of anticoagulation is paramount. For patients on dabigatran, the activated partial thromboplastin time (aPTT) increases with larger doses; however, the dose response is not linear and plateaus at higher concentrations of dabigatran. 3, 9 The prothrombin time (PT/INR) is variably affected but has been shown to rise with therapeutic doses. 9 The
INR is an insensitive measure of dabigatran activity and should not be used to monitor 
Rivaroxaban
Clinical Trials
Rivaroxaban is an oral direct inhibitor of activated Factor X (Xa), that is FDA approved for stroke and systemic embolization prevention in non-valvular atrial fibrillation and VTE prevention after knee and hip replacement. The ROCKET-AF trial randomized over 14,000 patients with atrial fibrillation and two stroke risk factors to rivaroxaban 20 mg daily or warfarin (Table 3) . Rivaroxaban was non-inferior to warfarin in prevention of stroke and systemic embolism (2.1%/year rivaroxaban versus 2.4%/year warfarin, p<0.001 non-inferiority). Major bleeding was equal between the rivaroxaban and warfarin groups at 5.6% and 5.4%, respectively. Fatal bleeding was 50% lower in the rivaroxaban group (0.4% versus 0.8%, p=0.003). Intracranial hemorrhage rates were also decreased with rivaroxaban (0.8% versus 1.2%, p=0.02). 12 Rivaroxaban was approved for prevention of stroke in patients with non-valvular atrial fibrillation in November 2011 (20 mg orally daily or 15 mg daily if creatinine clearance 15-50 ml/min). 13 After discontinuation of rivaroxaban in the ROCKET-AF trial, an increased risk of stroke was found, leading to a black box warning. 13 In order to maintain blinding in the trial at its completion, patients were not bridged when switching from rivaroxaban to warfarin.
Inadequate anticoagulation in high risk patients likely led to increased stroke risk.
The ATLAS-TIMI 46 and 51 studies used rivaroxaban in patients after acute coronary syndromes to reduce cardiovascular endpoints. 14, 15 Compared to placebo, rivaroxaban decreased the composite endpoint of cardiovascular death, myocardial infarction and stroke, but caused significantly higher major bleeding. The use of rivaroxaban after acute coronary syndromes currently is not standard of care.
In the RECORD trials, rivaroxaban was compared to enoxaparin for VTE prophylaxis after total knee and hip replacement. [16] [17] [18] [19] 21 This suggests that bleeding risk is low with rivaroxaban, but comparison to bleeding rates for long term anticoagulation on warfarin would require extrapolation from other studies.
Laboratory Testing
Routine laboratory monitoring of rivaroxaban is not required. As Factor X is a part of the common coagulation pathway, inhibitors of Factor Xa should prolong the PT and aPTT.
The degree of prolongation is dependent on the reagent used. No effect was seen on the TT or fibrinogen activity assays. 22 Dose-dependent prolongation of TEG parameters (R and K times) has been reported. 23 Chromogenic anti-Xa assays can be standardized to measure rivaroxaban, but this test may not be routinely available.
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Apixaban
Clinical Trials
Apixaban is an oral direct Factor Xa inhibitor that has completed several phase III trials but has not yet been approved by the FDA (Table 4) . Apixaban has been studied in two large trials in patients with atrial fibrillation. The AVERROES trial randomized 5600 patients unsuitable for warfarin therapy to apixaban 5 mg twice daily versus aspirin. With a mean follow-up of 1.1 years, the trial was stopped early for benefit as the rate of stroke or systemic embolism was 3.7%/year in the aspirin group versus 1.6%/year with apixaban. Similar rates of bleeding were seen in both treatment groups including rates of intracranial hemorrhage (0.4%/year in both groups). 25 This trial has been criticized because of the lack of standardization of the aspirin dose and the use of enteric-coated aspirin. The ARISTOTLE trial compared apixaban 5 mg twice daily to warfarin in over 18,000 patients with atrial fibrillation and one stroke risk factor. Apixaban was superior to warfarin in prevention of stroke or systemic embolization. The rate of hemorrhagic stroke was reduced by half with apixaban (0.24%/year apixaban versus 0.47%/year warfarin; p<0.001). The rate of death from any cause was also lower in the apixaban group (HR 0.89, p=0.047). Intracranial hemorrhage was reduced from 0.8%/year with warfarin to 0.33%/year with apixaban (p<0.001). Major bleeding occurred significantly less often with apixaban compared to warfarin and a 7.7% absolute risk reduction for all bleeding was noted with apixaban (p<0.001). 26 Overall, apixaban appears to be an effective alternative to warfarin for prevention of stroke and systemic embolism in patients with atrial fibrillation.
A phase II and III study tested the use of apixaban with antiplatelet therapy after acute coronary syndromes. 27, 28 The APPRAISE-2 study was discontinued early due to increased major bleeding without a decrease in the composite primary endpoint of cardiovascular death, recurrent myocardial infarction and stroke.
Apixaban has been evaluated in prevention but not treatment of VTE. The ADVANCE trials have examined the use of apixaban 2.5 mg twice daily versus enoxaparin in prophylaxis of VTE after orthopedic surgery. When compared to enoxaparin 30 mg twice daily, apixaban failed non-inferiority to enoxaparin with rates of VTE and all-cause mortality in 9% of the apixaban and 8.9% of the enoxaparin groups 29 . However, when compared to the European regimen of enoxaparin 40 mg daily, apixaban was found to be superior with equal bleeding rates after total knee and hip replacement.
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Laboratory Testing
Apixaban has a mechanism of action similar to rivaroxaban with direct inhibition of Factor Xa. Apixaban also prolongs the aPTT and PT levels with variability in the PT depending on the reagents used in testing. The linear correlation of the plasma concentration of apixaban and anti-Xa levels standardized to apixaban or to low molecular weight heparin are equally strong (r=0.967). Therefore, recalibration of antiXa testing may not be necessary to determine the degree of anticoagulation with apixaban.
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Management of Bleeding With New Oral Anticoagulants
The bleeding rates with the new oral anticoagulants are generally equal to or less than bleeding rates with warfarin, but antidotes are not available. Figure 1 shows the sites of action of the new oral anticoagulants and hemostatic agents that could be utilized.
Algorithms for managing hemorrhage in patients on dabigatran have been developed. 33 A
proposed management guideline is presented in Figure 2 .
Initial evaluation for bleeding patients on the new oral anticoagulants includes an assessment of hemodynamic stability, severity of bleeding, and level of anticoagulation. In cases of significant bleeding, additional hemostatic agents should be considered (Table   5 ). Antifibrinolytic medication provides clot stabilization if fibrin is able to form. In a large randomized trial of injured patients not taking the new oral anticoagulants, tranexamic acid was shown to decrease the risk of death due to hemorrhage when given within the first 3 hours of injury. 36 Antifibrinolytic agents have been ineffective in reducing bleeding times with direct thrombin inhibitors and may not be useful for patients taking dabigatran. 3 A recent prospective case series suggests decreased postoperative blood loss in patients treated with both rivaroxaban prophylaxis and tranexamic acid. 37 Reversal agents for the new oral anticoagulants including an inactivated Xa product are in development, but are not currently available. 38 In healthy subjects, the anticoagulant effect of rivaroxaban can be reversed with administration of 50 units/kg of Cofact® (Sanquin, Amsterdam, Netherlands), a non-activated 4-factor prothrombin complex concentrate (PCC) ( Table 5 ). In patients on dabigatran, clotting times remained prolonged after PCC infusion showing inadequate reversal of anticoagulation effect. 39 In a rat tail model of bleeding, recombinant activated Factor VII, non-activated 4-factor PCC and activated PCC were shown to significantly reduce bleeding times in dabigatran treated animals. 3, 40 Laboratory coagulation tests did not predict the reversal of bleeding in the mice, however. 40 In a mouse model of intracranial hemorrhage with dabigatran use, a non-activated 4-factor PCC prevented hematoma expansion but activated Factor VII did not have an effect. 41 Clinical data on dabigatran and rivaroxaban reversal using PCCs and activated Factor VII in humans is not available. Additionally, 4-factor PCCs are not available in the US (Table 5 ). Thrombosis and disseminated intravascular coagulation have occurred with administration of activated Factor VII and activated and nonactivated PCCs. Therefore, the risk of hemorrhage needs to be weighed against the risk of using any of these procoagulant agents and patients must be monitored closely.
Perioperative Management
Timing of anticoagulant discontinuation prior to surgery depends on the half-life of the anticoagulant, the patient's renal function, and the surgical risk of bleeding. Creatinine clearance plays the largest role in perioperative management of dabigatran. Table 6 summarizes recommendations regarding timing of discontinuation in standard risk procedures. High risk procedures including cardiac surgery, neurosurgery, abdominal surgery or procedures requiring spinal anesthesia may require 2-4 days off dabigatran in patients with normal renal function and 4 days off therapy with creatinine clearance 30-50 ml/min. 3 Checking an ECT or TT in patients with renal impairment on dabigatran is an option to ensure that minimal anticoagulant effect remains prior to the procedure.
Rivaroxaban has a significantly shorter half-life than dabigatran and thus could be discontinued 24 hours prior to surgery. 13 The half-life of rivaroxaban in elderly patients increases, so 48 hours may be necessary to allow for proper elimination. An increased risk of stroke has been reported after discontinuation of rivaroxaban, thus, minimizing the duration without anticoagulation in high risk patients is recommended. 13 In elderly patients, higher levels of apixaban have been reported. Providers should consider discontinuing apixaban for 48 hours or checking an anti-Xa level prior to surgery. 42 Timing of resumption of the new anticoagulants after surgery is dependent on bleeding risks and the dose used. It is important to remember that these drugs fully anticoagulate the patient in 2 -4 hours. In clinical trials for VTE prophylaxis after orthopedic surgery dabigatran was initiated at a half dose 1-4 hours after surgery and full dose 12 hours later. 6 Rivaroxaban was initiated 6-8 hours after wound closure and apixaban was started 12-24 hours postoperatively. 20, 43 For procedures with low bleeding risk, full anticoagulation with apixaban could be restarted after 24 hours; whereas resumption of anticoagulation after major surgery could be considered 48 hours post-operatively. 43 Additional clinical data and experience with the new anticoagulants will influence perioperative and postoperative management in the future. 
Conclusion
Case Reports of Factor Concentrate Use in Bleeding Patients
Since publication of my manuscript, "New Anticoagulants: A Concise Review," several case reports of management of bleeding patients taking dabigatran have been reported.
The reported effectiveness of recombinant activated factor VIIa (rfVIIa) has varied depending on the clinical situation. In a patient with atrial fibrillation on dabigatran and excessive bleeding post-operatively, 5 doses of recombinant activated factor VIIa (rfVIIa) decreased bleeding sufficiently to allow transfer from the operating room;
however, hemodialysis lead to the most significant decrease in dabigatran concentration and bleeding. 56 Two case reports from the neurosurgical literature showed persistent hemorrhage after rfVIIa in elderly patients on dabigatran. 57, 58 Only three case reports of use of other factor concentrates in dabigatran associated hemorrhage have been published. In a patient with cardiac perforation during an atrial fibrillation ablation, administration of aPCC lead to hemostasis within minutes of administration. 59 Use of a 3-factor PCC in a patient with an upper gastrointestinal hemorrhage lead to improvement in the INR and aPTT and no further bleeding occurred. 60 In a similar clinical situation, administration of 3-factor PCC lead to hemoglobin stabilization after an upper gastrointestinal hemorrhage, but the patient died of multiorgan failure. 61 No case reports of management of rivaroxaban associated hemorrhage have been published. Overall, human data on the most effective management strategies for bleeding in patients taking the new oral anticoagulants is limited and conflicting.
Thesis Research Project
Post-marketing surveillance has reported major bleeding events in patients taking dabigatran. 62 Anecdotally, physicians have also cared for patients hemorrhaging after 
Results and Discussion
Overall response rate was 31.5% (48/152 surveyed) and 92% of respondents completed the survey. Our response rate was within previously published ranges of physicians' response to electronic surveys without incentives. 66, 67 No significant differences in demographic or practice characteristics were found between survey respondents and nonrespondents ( Table 7) . The lack of difference in baseline characteristics between respondents and non-respondents decreases but does not eliminate the possibility of nonresponse bias in our survey results.
Detailed management information was provided in 22 of 43 reported cases of dabigatranassociated bleeding ( (Table 2) . Dabigatran was withheld in all reported cases of dabigatran bleeding and was considered the most effective strategy in 82% of patients. Factor concentrates were used in 9 patients experiencing major bleeding on dabigatran. Reported doses were lower than recommended to treat hemophilia, [68] [69] [70] and multiple doses of activated prothrombin complex concentrates (aPCC) and recombinant activated factor VII (rfVIIa) were used.
Factor concentrates were perceived as effective in 50-80% of the patients bleeding with dabigatran. In the 2 cases where both prothrombin complex concentrates (PCC) and rfVIIa were given, both were considered effective by the treating physician.
Unfortunately, the limited number of bleeding patients managed with factor concentrates does not allow for recommendations of one concentrate over another.
Fewer cases of rivaroxaban-associated bleeding were reported (Table 8) . Similar to dabigatran, management of bleeding involved withholding the drug and local measures.
aPCC was administered in 1 case. All interventions used to treat rivaroxaban-associated bleeding were perceived as effective. These patients are the first reported cases of managing rivaroxaban-associated bleeding in the literature.
Algorithms to manage bleeding patients have been proposed by several authors based on animal data and expert opinion. 64, 63 Management algorithms were available at 12 (25%) of the respondents' institutions. Only 25% of the algorithms recommended antifibrinolytic medication, whereas all but one algorithm contained the use of factor concentrate (50% aPCC, 66% PCC, and 83% rfVIIa). Nine of the 12 institutional algorithms contained more than one factor concentrate. Factor concentrates were widely available; 62% of institutions had PCC, 87% had aPCC, and 98% had rfVIIa on-site.
Only three bleeding patients were managed at hospitals with treatment algorithms; thus, inferences as to the influence of the treatment algorithm on the management strategy cannot be made. ECT was used in only 23% of dabigatran bleeding episodes, and these cases were managed in 2 of the 10 hospitals that had ECT available on-site. Laboratory assessment of bleeding patients on dabigatran is challenging because the assays most efficacious in overdose settings, ECT and diluted TT, are not widely available even at academic centers.
Similar to the dabigatran bleeding cases, 60% of the rivaroxaban bleeding patients were evaluated with PT/INR and 100% with aPTT. Chromogenic anti-Xa assays can be standardized to measure rivaroxaban 24 and rivaroxaban anticoagulation was assessed using an anti-Xa assay in all reported bleeding cases. Anti-Xa assays were available onsite in 91% of the respondents' hospitals including academic, academic affiliated and community practices. Therefore, the ability to measure rivaroxaban anticoagulation via anti-Xa is more accessible than assays for dabigatran.
A majority of physicians remain concerned about their ability to manage bleeding patients on the new oral anticoagulants; 27% of physicians reported moderate concern, 30% noted moderately high and 25% reported high concern. Only 9% of physicians reported mild and no concern. Physicians with moderate to high levels of concern attributed their apprehension to lack of established effective management, antidote, or experience with managing bleeding patients. Whereas physicians with only mild concern referenced infrequent major bleeding rates as the reason for their minimal concern.
Average level of concern was lower in physicians who participated in clinical trials than in physicians who had not participated in trials, but this was not statistically significant (Mean 2.6 vs 3.6, p=0.07). Level of concern was not associated with years in practice, number of cases managed, or availability of treatment algorithm. Respondents' high level of concern regarding their ability to manage hemorrhage illustrates the unease associated with widespread use of the new anticoagulants.
Our survey results show management of dabigatran and rivaroxaban-associated bleeding varies. Effective management included withholding the drug or local measures in most cases. Factor concentrates were prescribed in 41% of dabigatran-associated bleeding, but a specific product cannot be recommended because of similar frequency of concentrate use and perceived effectiveness. Surprisingly, most academic institutions do not have diluted TT or ECT to measure elevated concentrations of dabigatran; whereas anti-Xa assays are widely available. Non-malignant hematologists remain concerned about their ability to manage patients, which reiterates the need for national registries or multicenter trials to determine the best management strategy for dabigatran and rivaroxabanassociated bleeding.
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PCC=prothrombin complex concentrate, aPCC= activated prothrombin complex concentrate, rfVIIa=recombinant activated Factor VII.
